Study guide
7.3 Component Receipt, Storage & Material Transfer
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
7.3 Component Receipt, Storage & Material Transfer
Key Takeaways Explain This Topic AI
On receipt, personnel check each lot's external packaging, labeling and condition, including temperature indicators. Unacceptable components are rejected, labeled as rejected, segregated, and other lots from that vendor are checked.
Components are stored closed, under their labeled temperature, humidity and light conditions. Storage temperature is monitored at least daily on open days (or continuously) and documented, and monitoring devices are verified every 12 months unless the manufacturer says otherwise.
Before items go onto the clean side of the anteroom, into a pass-through or into an SCA, gloved personnel wipe them with a sporicidal disinfectant, an EPA-registered disinfectant or sterile 70% IPA, allowing contact time or drying.
Just before entering the PEC, items are wiped with sterile 70% IPA, except that sterile items in sealed sterile packaging may be removed from the wrap as they are introduced.
Under USP <800>, antineoplastic HDs and HD APIs are unpacked in a neutral or negative-pressure area, never a sterile compounding or positive-pressure area. Those that need manipulation are stored separately in an externally vented, negative-pressure room with at least 12 air changes per hour.
Last updated: September 2026
7.3 Component Receipt, Storage & Material Transfer
Contamination often enters a cleanroom on things rather than people: a damaged vial, a carton dusted with spores, a warm refrigerated drug, or a bag wiped without enough contact time. The BCSCP outline covers component handling (task 1A5) from receipt through storage to transfer into the PEC. USP <797> Sections 8 and 9.3 set the rules, and USP <800> adds hazardous drug controls.
Receiving (USP <797> 9.3.2)
When each lot arrives, personnel:
Examine the external packaging for damage and deterioration.
Verify the labeling and condition , including whether the outer packaging is damaged and whether temperature-sensing indicators show exposure to excessive temperature.
Reject unacceptable components promptly. They are clearly labeled as rejected and segregated from active stock until disposed of. Other lots from the same vendor are examined for the same defect.
Mark the date of receipt on any API or added-substance package that has no vendor expiration date, and assign a conservative expiration date of no more than 1 year after receipt.
Check supply chain status. Verify that the prescription drug came from an authorized trading partner with the required DSCSA transaction data, and quarantine suspect product (see 11.3).
Evaluation before use (9.3.3)
Before use, compounders confirm that every component has the correct identity and appropriate quality , is within its expiry , and has been stored properly . Packages are reinspected for breaks, loose caps or closures, and changes in appearance, aroma or texture. Sterile closures are reinspected for defects that could compromise sterility. Anything unacceptable is rejected, labeled and segregated, and other lots are checked.
Storage (9.3.4 and 19.1)
- Requirement Detail
- Containers Closed, stored to prevent contamination, mix-ups and deterioration
- Conditions Temperature, humidity and light as the monograph or supplier specifies (USP <659> ranges)
Temperature monitoring Manually at least once daily on days the facility is open, or with a continuous recorder
- Records A temperature log, or retrievable data in the continuous device
- Device accuracy Calibrated or verified as the manufacturer recommends, or every 12 months if unspecified
- Excursions Detected and minimized; affected items are evaluated before use
Keep sterile compounding stock out of areas that generate particles. Store look-alike and sound-alike products apart. High-alert concentrates such as potassium chloride and hypertonic saline belong in segregated, labeled storage.
Moving materials into classified space (Section 8)
Loading diagram...
Into the SEC or SCA (8.1). Before any item goes onto the clean side of an anteroom, into a pass-through chamber, or into an SCA, it is wiped, if the packaging allows, with a sporicidal disinfectant, an EPA-registered disinfectant, or sterile 70% IPA . Low-lint wipers are used, and the person wiping wears gloves. An EPA-registered disinfectant or sporicidal must stay wet for its minimum contact time , and IPA must dry . Wiping must not damage the packaging or make the label unreadable.
Into the PEC (8.2). Just before an item enters the PEC, it is wiped with sterile 70% IPA on a sterile low-lint wiper and allowed to dry. Sterile items in sealed sterile packaging may be removed from the wrap as they go into the ISO Class 5 space, without wiping each item.
Critical sites (8.3). Vial stoppers, ampule necks and bag septums are wiped with sterile 70% IPA in the PEC and allowed to dry before they are punctured or opened.
Transport inside the facility. Carts must be cleanable, and a cart is not taken from the dirty side to the clean side unless the whole cart is cleaned. Materials that have been in patient care areas are not brought into anterooms, buffer rooms or SCAs unless thoroughly cleaned and disinfected.
Hazardous drug components (USP <800>)
Step USP <800> requirement
Unpacking Antineoplastic HDs and all HD APIs are unpacked (removed from shipping containers) in a neutral/normal or negative-pressure area. Never in sterile compounding areas or positive-pressure areas
PPE at receipt Chemotherapy gloves (ASTM D6978) when unpacking. A spill kit is available in the receiving area
Damaged shipments Treated as spills and reported to the designated person. Opening them in a C-PEC is preferred. If only a sterile-compounding C-PEC is available, it must be deactivated, decontaminated, cleaned and disinfected before sterile work resumes
Storage Antineoplastic HDs that need manipulation (other than counting or repackaging) and all HD APIs are stored separately from non-HDs , in an externally vented, negative-pressure room with at least 12 ACPH , and not on the floor
Refrigerated HDs Kept in a dedicated refrigerator in a negative-pressure area with at least 12 ACPH (a storage room, buffer room or C-SCA)
- Transport Clearly labeled. Never sent through pneumatic tubes if liquid or antineoplastic
- Wiping HD packaging The solution used must not alter the product label
HDs that return to the supplier wait in a designated negative-pressure area.